Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).

导出 LinkOut

翻译打印收藏纠错

作者： Sant P,Chawla ^[1] ; Steven,Wong ^[1] ; Doris,Quon ^[1] ; Ania,Moradkhani ^[1] ; Victoria S,Chua ^[1] ; Don A,Brigham ^[2] ; Rebecca A,Reed ^[2] ; William,Swaney ^[3] ; Frederick L,Hall ^[2] ; Erlinda M,Gordon ^[4]

作者单位： Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, United States. ^[1] Aveni Foundation, Santa Monica, CA, United States. ^[2] Expression Therapeutics, Tucker, GA, United States. ^[3] Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, United States.;Aveni Foundation, Santa Monica, CA, United States. ^[4]

关键词 CCNG1 DeltaRex-G basal cell carcinoma breast cancer cancer gene therapy cyclin G1 inhibitor pancreatic cancer sarcoma

DOI 10.3389/fmmed.2022.1092286

PMID 39086973

发布时间 2024-08-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in molecular medicine

2022年2卷

1092286页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).

Frontiers in molecular medicine

相似文献

Frontiers in molecular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130).

Frontiers in molecular medicine

相似文献

Frontiers in molecular medicine

相关期刊

检索历史清除